Effient

Angina, Unstable, Percutaneous Coronary Intervention, Percutaneous Coronary Intervention + 2 more

Treatment

6 FDA approvals

5 Active Studies for Effient

What is Effient

Prasugrel

The Generic name of this drug

Treatment Summary

Prasugrel is a medication used to reduce the risk of heart attack and stroke by preventing platelet activation and aggregation. It works by binding to a certain type of ADP receptor on platelets, which in turn inhibits the GPIIb/IIIa receptor complex and prevents platelets from sticking together. Prasugrel was developed by Daiichi Sankyo Co. and FDA approved in 2009, and it is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI).

Effient

is the brand name

image of different drug pills on a surface

Effient Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Effient

Prasugrel

2009

37

Approved as Treatment by the FDA

Prasugrel, otherwise called Effient, is approved by the FDA for 6 uses including Percutaneous coronary intervention, Unstable angina and Percutaneous Coronary Intervention .

Percutaneous coronary intervention, Unstable angina

Percutaneous Coronary Intervention

prophylaxis of cardiovascular event

Angina, Unstable

Cardiovascular Events

Percutaneous Coronary Intervention

Effectiveness

How Effient Affects Patients

Prasugrel is a type of medicine that stops platelets from clumping together and forming clots. It does this by attaching to a specific receptor (P2Y12) in the body and blocking it. The effect is irreversible.

How Effient works in the body

Prasugrel is a drug that stops platelets in your blood from sticking together, which prevents blood clots. It does this by blocking a receptor on platelets called P2Y12. Prasugrel works similarly to another drug, clopidogrel.

When to interrupt dosage

The proposed dosage of Effient is determined by the diagnosed affliction, including Percutaneous Coronary Intervention, Angina, Unstable and prophylaxis of cardiovascular event. The measure of dosage fluctuates, depending on the technique of delivery (e.g. Tablet, film coated - Oral or Tablet, coated - Oral) as indicated in the table below.

Condition

Dosage

Administration

Angina, Unstable

, 10.0 mg, 5.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Percutaneous Coronary Intervention

, 10.0 mg, 5.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Percutaneous Coronary Intervention

, 10.0 mg, 5.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

prophylaxis of cardiovascular event

, 10.0 mg, 5.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Cardiovascular Events

, 10.0 mg, 5.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

Effient Contraindications

Condition

Risk Level

Notes

Ischemic Attack, Transient

Do Not Combine

Hemorrhage

Do Not Combine

Stroke

Do Not Combine

There are 20 known major drug interactions with Effient.

Common Effient Drug Interactions

Drug Name

Risk Level

Description

Abrocitinib

Major

The risk or severity of bleeding and thrombocytopenia can be increased when Prasugrel is combined with Abrocitinib.

Albutrepenonacog alfa

Major

The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Prasugrel.

Andexanet alfa

Major

The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Prasugrel.

Anti-inhibitor coagulant complex

Major

The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Prasugrel.

Antihemophilic factor (recombinant), PEGylated

Major

The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Prasugrel.

Effient Toxicity & Overdose Risk

The level of toxicity for this drug is high, with the lethal dose for rats being between 1,000 to 2,000 mg/kg and the lethal dose for rabbits being greater than 1,000 mg/kg.

image of a doctor in a lab doing drug, clinical research

Effient Novel Uses: Which Conditions Have a Clinical Trial Featuring Effient?

Three active clinical trials are currently evaluating the potential of Effient for Percutaneous Coronary Intervention, Percutaneous Coronary Intervention and Unstable Angina.

Condition

Clinical Trials

Trial Phases

Percutaneous Coronary Intervention

0 Actively Recruiting

Cardiovascular Events

4 Actively Recruiting

Not Applicable

Angina, Unstable

0 Actively Recruiting

prophylaxis of cardiovascular event

0 Actively Recruiting

Percutaneous Coronary Intervention

0 Actively Recruiting

Effient Reviews: What are patients saying about Effient?

5

Patient Review

12/18/2015

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

The only issue I had was that I couldn't take Metformin.

5

Patient Review

8/5/2015

Effient for Myocardial Reinfarction Prevention

After my stent procedure in 2011, my cardiologist put me on Effient. I had no side effects whatsoever!

5

Patient Review

9/18/2014

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I started using this drug immediately after I had a stint installed in my heart. No side effects.

4.7

Patient Review

5/29/2017

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I haven't experienced any negative effects from this medication, other than the bruises that show up when I accidentally hit my arms or hands. The price is a bit high, but luckily my doctor sometimes has samples on hand.

4.3

Patient Review

7/12/2014

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

This medication is effective, but I'm keeping an eye out for any potential food interactions. So far, no problems while drinking green juice regularly.

4

Patient Review

11/5/2015

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I experienced some lightheadedness, headaches, and tightness in my chest when first taking this medication. However, I hope that my body will adjust to it over time.

4

Patient Review

5/4/2014

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I have found that this medication sometimes makes it difficult for me to fall asleep. Additionally, I will sometimes experience my body jerking involuntarily.

4

Patient Review

10/5/2016

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

So far, the only side effects I've experienced are easy bruising and slightly more difficult to stop bleeding. All things considered, this treatment is going well!

4

Patient Review

5/20/2014

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

So far, so good. I am seeing the positive effects I was hoping for. The only downside is that I'm not sure if it will start causing insomnia.

3.7

Patient Review

5/13/2017

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I was put on a 10MG dosage of Effient in 2017 following my first stent. I experienced massive bruising on one side of my body. My cardiologist reduced the dosage to 5MG and I had a blood workup done to check for any bleeding (which came back negative). I also experienced red blotches on my face and 3 nose bleeds (very small). In addition, I felt tired and had no energy.

3

Patient Review

3/14/2015

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I'm not a fan of the random bleeding, but it's manageable. My real issue is the sudden weakness in my legs; it happens often and makes everyday activities really tough. I've been wondering if this could be age-related since I'm 79, but my cardiologist insists that I need to stay on my current dosage of 10 mg Effient + 81 mg aspirin.

2.7

Patient Review

3/25/2014

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I had a stent put in September 2013 and started taking Effient in October. Now it's February 2014, and I've been feeling very weak, with fever, muscle aches, and shortness of breath. Hopefully my regular doctor will be able to give me something else that will work better.

1.7

Patient Review

2/4/2014

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

1

Patient Review

5/10/2015

Effient for Blood Clot Prevention Following Percutaneous Coronary Intervention

I was taken off Plavix and put on this drug while in the hospital following an angioplasty and stent (my 7th) implacement. I immediately started having great difficulty breathing - felt like I was drowning. I insisted they discontinue the Effient and put me back on the Plavix. Bingo - breathing difficulty resolved.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about effient

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Plavix and Effient the same?

"Plavix becomes an active drug after undergoing two chemical reactions. Dr. Sep 17, 2009 stated that Effient is more beneficial than Plavix because it is more efficient in preventing platelets from stick together."

Answered by AI

What is Effient used for?

"This medication helps prevent other serious heart and blood vessel problems, such as heart attacks, strokes, and blood clots in stents, by blocking platelets from sticking together and forming harmful blood clots."

Answered by AI

What kind of drug is Effient?

"Effient is an antiplatelet drug designed to prevent the formation of blood clots, which can lead to heart attacks."

Answered by AI

Is Effient and eliquis the same?

"Effient and Eliquis are both drugs that have side effects that include increased bleeding, nausea, and skin rash."

Answered by AI

Clinical Trials for Effient

Image of Brigham and Women's Hospital in Boston, United States.

Rosuvastatin for Cancer-Associated Blood Clots

18+
All Sexes
Boston, MA

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

Phase 4
Waitlist Available

Brigham and Women's Hospital (+1 Sites)

Have you considered Effient clinical trials?

We made a collection of clinical trials featuring Effient, we think they might fit your search criteria.
Go to Trials